Key Points
- Solomon Moshkevich sold 3,000 Natera shares on Dec. 1 at an average price of $238.15 for $714,450, leaving him with 109,061 shares (a 2.68% ownership decrease) — part of a string of recent insider sales.
- Natera missed on quarterly EPS at ($0.64) versus a ($0.39) consensus but reported revenue of $592.18 million (up 34.7% YoY), beating estimates.
- Analysts hold a consensus rating of Moderate Buy with a $223.53 target, and several firms have recently raised price targets (some up to $250), while institutional investors own 99.90% of the stock.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $238.15, for a total value of $714,450.00. Following the completion of the sale, the insider owned 109,061 shares in the company, valued at approximately $25,972,877.15. This represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Solomon Moshkevich also recently made the following trade(s):
- On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.
- On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total value of $229,369.08.
- On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $193,858.56.
- On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The shares were sold at an average price of $187.95, for a total transaction of $54,881.40.
- On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00.
Natera Trading Up 0.7%
Shares of NTRA opened at $238.21 on Thursday. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $241.28. The firm's 50-day moving average price is $196.35 and its 200-day moving average price is $172.56. The firm has a market capitalization of $32.88 billion, a price-to-earnings ratio of -104.02 and a beta of 1.63.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera's quarterly revenue was up 34.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.26) earnings per share. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Hedge Funds Weigh In On Natera
Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Natera by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company's stock valued at $2,141,594,000 after purchasing an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company's stock worth $1,871,914,000 after buying an additional 1,003,129 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after buying an additional 3,795,315 shares during the last quarter. State Street Corp grew its holdings in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock valued at $545,624,000 after buying an additional 72,087 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company's stock valued at $428,987,000 after acquiring an additional 727,366 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently commented on NTRA shares. BNP Paribas upgraded Natera to a "hold" rating and set a $172.00 target price for the company in a research note on Monday, October 27th. JPMorgan Chase & Co. increased their price objective on Natera from $240.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, November 25th. Stephens raised their price objective on Natera from $197.00 to $235.00 and gave the company an "overweight" rating in a research report on Thursday, November 13th. Barclays boosted their target price on shares of Natera from $210.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, November 7th. Finally, Evercore ISI increased their price target on shares of Natera from $190.00 to $250.00 and gave the stock an "outperform" rating in a research note on Friday, November 7th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Natera has a consensus rating of "Moderate Buy" and a consensus target price of $223.53.
Check Out Our Latest Analysis on NTRA
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
